Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

BACKGROUND AND AIMS A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Si...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sarah Blach, Christian Schaetti, Philip Bruggmann, Francesco Negro, Homie Razavi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2019-03-01
Serie:	Swiss Medical Weekly
Soggetti:	Cost-effectiveness direct acting antivirals hepatitis C virus hepatocellular carcinoma liver cirrhosis quality-adjusted life years
Accesso online:	https://www.smw.ch/index.php/smw/article/view/2598
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!